Parasitel is a prescription medication utilized in a therapeutic context to address certain infections caused by parasites in adults and children. Its authorized uses involve managing specific conditions resulting from parasitic worms.

Quick Facts: Therapeutic Applications

• Addresses parenchymal neurocysticercosis, which is associated with active lesions from the larval form of the Taenia solium (pork tapeworm).
• Indicated for cystic hydatid disease affecting the liver, lung, and peritoneum, a condition connected to the larval form of the Echinococcus granulosus (dog tapeworm).
• May be used to support the resolution of other parasitic infections as determined by a healthcare provider.

The medication acts by interfering with the organism's ability to thrive, a process that assists the body in clearing the infection. Treatment regimens are administered under the direct guidance of a medical professional.

Regulatory References

1. NIH MedlinePlus guidance

Official Eligibility Status for Parasitel (Human Use)

This section defines the official eligibility and non-eligibility profiles for the medicine Parasitel, based strictly on authoritative regulatory documentation from government health agencies worldwide.

Regulatory Status and Eligibility Constraint

The product name Parasitel for human use is not found within the official regulatory databases and public assessment reports of major governmental drug authorities, including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and others globally. Consequently, there is no established official regulatory profile for this product.

Eligibility Classification	Status Based on Official Regulatory Data
Use Authorization	None (No approved label exists)
Eligible Populations	None are defined in regulatory documents
Contraindicated Populations	Not officially documented (Requires an approved label)
Age-Related Rules	Use Not Established for any age group
Physiological/Condition Restrictions	Not officially documented

Resulting Eligibility Structure

Since no approved Summary of Product Characteristics, Prescribing Information, or government monograph has been issued for Parasitel, the medicine is subject to a universal non-eligibility constraint for the general population. This means that no person is officially authorized to use this medicine under standard, licensed regulatory frameworks. All populations are considered to have a Use Not Established status until a governmental agency authorizes a complete regulatory label that defines the full safety and user profiles.

The official interaction profile, primarily based on the components Albendazole and Praziquantel, is defined by significant alterations in the plasma concentration of their active metabolites.

Pharmacokinetic Interactions

Interacting Medicinal Products and Classes:

• Exposure-Increasing Agents: Cimetidine, Dexamethasone, and Praziquantel are documented to increase the exposure (AUC and C max) of the active Albendazole sulfoxide metabolite. Cimetidine specifically increases its concentration in bile and cystic fluid by approximately two-fold.
• Exposure-Decreasing Agents: Strong Cytochrome P450 (CYP) enzyme inducers, notably Rifampin, and anticonvulsants such as Phenytoin and Carbamazepine, decrease the plasma levels of Albendazole's active metabolite. Rifampin also significantly reduces Praziquantel plasma concentrations.

Non-Medicinal and Population-Specific Interactions

Food and Herbal Products:

• Grapefruit Juice is documented to increase the plasma concentration of both Praziquantel and Albendazole's active metabolite.
• Co-administration of Albendazole with a fatty meal increases its active metabolite concentration by up to five-fold compared to the fasted state.

Interaction-Related Restrictions:

• Concomitant use of Praziquantel with Rifampin is contraindicated due to the inability to achieve therapeutically effective drug levels. If Praziquantel treatment is necessary, Rifampin must be discontinued four weeks prior.
• Patients with hepatic impairment require monitoring as reduced metabolism can lead to higher and more sustained Praziquantel plasma concentrations.

The mechanism of action for Albendazole (Parasitel) involves two primary actions that target the parasitic organism's structural integrity and energy supply. The effect is selective, leveraging differences between parasite and host cell biology.

---

Inhibiting the Parasite's Microtubule Structure

This domain covers the primary molecular interaction: the active metabolite of the drug selectively binds to beta-tubulin, inhibiting the assembly of essential microtubules. This structural disruption is a necessary step, as it immediately compromises the physical integrity and functional capacity of the parasite's nutrient-absorbing cells.

---

Inducing Metabolic Energy Collapse

This key pathway effect results from the structural damage; the disruption of microtubules functionally blocks glucose transporters on the parasite's surface. This leads to the rapid and profound depletion of glycogen reserves and ATP (energy), causing the immobilization, stasis, and eventual death of the organism. The mechanism modulates key processes that govern energy metabolism and cellular homeostasis, resulting in the failure of core survival functions.

Administration Guidelines for Parasitel

Parasitel (praziquantel) is administered orally and follows a single-day, three-dose treatment schedule. Strict adherence to the dosing and procedural steps is required for use in patients aged 1 year and older.

Dosing and Timing

Condition	Dosage (Body Weight Dependent)	Frequency & Duration	Timing Constraint
Schistosomiasis	20 mg/kg bodyweight	Three times in 1 day	Doses must be separated by 4 to 6 hours
Clonorchiasis / Opisthorchiasis	25 mg/kg bodyweight	Three times in 1 day	Doses must be separated by 4 to 6 hours

Tablets should be taken with water during meals to ensure proper administration. The medication is provided as 600 mg tablets with three scores, which allows the tablet to be broken into four 150 mg segments for precise bodyweight-based dosing.

Preparation and Special Conditions

• Do not chew or hold the tablets or tablet segments in the mouth, as the intense bitter taste may cause gagging or vomiting.
• For pediatric patients under 6 years of age, the tablets may be crushed or disintegrated and mixed with semi-solid food or liquid. Any crushed or disintegrated tablets must be used within 1 hour of preparation.

Missed Dose: Since the treatment is completed in a single day, instructions for a missed dose are typically not applicable; however, patients must adhere to the prescribed 4 to 6-hour interval between the three doses. Consult a healthcare provider if a scheduled dose interval is missed.

This protocol defines the procedure for a complete course of therapy, focusing on dose calculation, rapid swallowing, and maintaining the required interval between administrations to maximize drug concentration during the single treatment day.

Parasitel: Recent Clinical Evidence

Research examining the medicine containing Albendazole includes a variety of studies, primarily Randomized Controlled Trials (RCTs) and systematic reviews, which track disease markers and symptom patterns in patient groups.

---

Evidence for Use in Parenchymal Neurocysticercosis

Research has focused on understanding the structure of trials for neurocysticercosis, a condition involving larval parasites in the brain. RCTs and meta-analyses explored outcomes when using the medicine versus placebo or other protocols. Studies primarily monitored the resolution or disappearance of active cysts using neuroimaging, and tracked patterns of seizure activity. Trials reported measurements of cyst visibility and seizure patterns over defined time intervals. However, long-term effects are not fully established regarding the sustained tracking of seizures, and comparative evidence is lacking for a standardized regimen across all disease manifestations.

---

Evidence for Use in Soil-Transmitted Helminth Infections

Research examining these common infections was studied for acute or disruptive episodes, particularly in endemic regions. The evidence base includes RCTs and large-scale data analyses focused on measuring Egg Reduction Rates (ERRs) and Cure Rates (CRs) for species like roundworm and hookworm. Data show patterns related to the measured reduction in parasite egg counts. Findings indicate that the measured outcome may vary significantly depending on the specific parasite being studied, and follow-up durations were limited in many primary trials.

---

Research Gaps and Patient Populations

Research examined treatment outcomes primarily in adult patients and school-aged children in endemic regions. However, data for certain groups remain insufficient, particularly for pregnant women and older adult cohorts with comorbid conditions, where sample sizes were small or non-existent. Evidence for indications like lymphatic filariasis also exists, showing patterns of microfilarial density reduction. The evidence highlights what is known—and what is still uncertain—including the need for standardized dosing strategies for certain helminths. Research is currently underway to address these gaps in long-term outcomes and specific population data.

Common questions about Parasitel (FAQ)

---

Q: What is Parasitel used for?

According to official product information, Parasitel is indicated for the treatment of specific infections caused by certain intestinal parasites. It works by targeting and eliminating these organisms from the body. Regulatory documents state that it is used only when an infection is confirmed by laboratory testing.

---

Q: How long does it take for Parasitel to work?

Studies and official information indicate that the time it takes for Parasitel to have an effect varies depending on the specific parasite being treated. Regulatory information indicates the treatment course is designed to address the infection over a specific duration. The success of the treatment is typically confirmed by a healthcare provider, often through follow-up testing.

---

Q: What should I do if I miss a dose of Parasitel?

If a dose of Parasitel is missed, official product information generally advises the missed dose be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, skipping the missed one is usually recommended. The official guidance states that patients should avoid taking two doses simultaneously to compensate for a missed dose.

---

Q: Can I drink alcohol while taking Parasitel?

According to regulatory documents, consuming alcohol is not recommended during treatment with Parasitel and for a specific period after the final dose. Alcohol consumption can potentially increase the risk or severity of certain side effects. Patients should consult the official product information for guidance on the required duration of alcohol avoidance.

---

Q: Is Parasitel safe to use during pregnancy?

Official product information states that Parasitel is generally not recommended for use during pregnancy, especially during the first trimester. This is because there is limited or conflicting data on its potential effects on the developing fetus. The decision to use the medication during pregnancy requires a careful assessment of the potential benefits versus the risks by a healthcare professional.

---

Q: Does Parasitel interact with any common foods or supplements?

Regulatory documents mention that certain grapefruit products may interact with Parasitel and should be avoided during treatment. This is because they can affect how the medicine is processed by the body. No other major food or general supplement interactions are consistently highlighted in the official materials, but specific interactions with prescription medicines are noted.

---

Q: What is the active ingredient in Parasitel?

The active ingredient in Parasitel is Nitazoxanide, which is classified as an antiprotozoal agent. This is the substance responsible for the drug's therapeutic effect against certain parasites. The official product information specifies the concentration and form of this ingredient.

Storage and Disposal of Parasitel (Albendazole)

Parasitel must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted excursions up to 30 C. Official regulations require the product to be protected from excessive heat and moisture, and it must not be frozen. For stability, the medicine should remain in its original container, which must be kept tightly closed.

Handling and Safety

Mandatory storage instructions require keeping Parasitel out of the sight and reach of children.

Disposal

Expired or unused Parasitel must be disposed of in accordance with local requirements. The preferred method is using a medication take-back program. If this is not feasible, the medicine should be mixed with an undesirable substance (such as dirt), sealed in a bag, and discarded in the household trash. The product should not be flushed down a toilet or drain unless explicitly directed by regulatory authority.